Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data
| Autor: | Srikanth Neelakantham, Kerri A Schoedel, Kasra Shakeri-Nejad, Anne Gardin, Carine Kolly |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Ozanimod
Sphingosine 1 Phosphate Receptor Modulators medicine.medical_specialty Multiple Sclerosis medicine.medical_treatment Physical dependence Review Siponimod Abuse chemistry.chemical_compound Clinical Sphingosine medicine media_common.cataloged_instance Animals Humans S1P receptor modulator European union Psychiatry Adverse effect Dependence media_common Pharmacology business.industry Non-clinical Fingolimod Stimulant chemistry Ponesimod medicine.symptom Lysophospholipids business medicine.drug |
| Zdroj: | Psychopharmacology |
| ISSN: | 1432-2072 |
| Popis: | Abuse and misuse of prescription drugs remains an ongoing concern in the USA and worldwide; thus, all centrally active new drugs must be assessed for abuse and dependence potential. Sphingosine-1-phosphate (S1P) receptor modulators are used primarily in the treatment of multiple sclerosis. Among the new S1P receptor modulators, siponimod, ozanimod, and ponesimod have recently been approved in the USA, European Union (EU), and other countries. This review of literature and other public data has been undertaken to assess the potential for abuse of S1P receptor modulators, including ozanimod, siponimod, ponesimod, and fingolimod, as well as several similar compounds in development. The S1P receptor modulators have not shown chemical or pharmacological similarity to known drugs of abuse; have not shown abuse or dependence potential in animal models for subjective effects, reinforcement, or physical dependence; and do not have adverse event profiles demonstrating effects of interest to individuals who abuse drugs (such as sedative, stimulant, mood-elevating, or hallucinogenic effects). In addition, no reports of actual abuse, misuse, or dependence were identified in the scientific literature for fingolimod, which has been on the market since 2010 (USA) and 2011 (EU). Overall, the data suggest that S1P receptor modulators are not associated with significant potential for abuse or dependence, consistent with their unscheduled status in the USA and internationally. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink